JP7202287B2 - リンパ系疾患の診断及び治療のための組成物及び方法 - Google Patents

リンパ系疾患の診断及び治療のための組成物及び方法 Download PDF

Info

Publication number
JP7202287B2
JP7202287B2 JP2019511562A JP2019511562A JP7202287B2 JP 7202287 B2 JP7202287 B2 JP 7202287B2 JP 2019511562 A JP2019511562 A JP 2019511562A JP 2019511562 A JP2019511562 A JP 2019511562A JP 7202287 B2 JP7202287 B2 JP 7202287B2
Authority
JP
Japan
Prior art keywords
lymphatic
mtor
snv
inhibitors
abnormalities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533987A5 (enExample
JP2019533987A (ja
Inventor
ホーコン ハゥコーナルソン，
トン リー，
リーフォン ティエン，
ケニー グェン，
パトリック スレイマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2019533987A publication Critical patent/JP2019533987A/ja
Publication of JP2019533987A5 publication Critical patent/JP2019533987A5/ja
Priority to JP2022206535A priority Critical patent/JP2023052057A/ja
Application granted granted Critical
Publication of JP7202287B2 publication Critical patent/JP7202287B2/ja
Priority to JP2024169918A priority patent/JP2025016454A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019511562A 2016-08-31 2017-08-30 リンパ系疾患の診断及び治療のための組成物及び方法 Active JP7202287B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022206535A JP2023052057A (ja) 2016-08-31 2022-12-23 リンパ系疾患の診断及び治療のための組成物及び方法
JP2024169918A JP2025016454A (ja) 2016-08-31 2024-09-30 リンパ系疾患の診断及び治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382147P 2016-08-31 2016-08-31
US62/382,147 2016-08-31
PCT/US2017/049453 WO2018045078A2 (en) 2016-08-31 2017-08-30 Compositions and methods for the diagnosis and treatment of lymphatic system disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022206535A Division JP2023052057A (ja) 2016-08-31 2022-12-23 リンパ系疾患の診断及び治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019533987A JP2019533987A (ja) 2019-11-28
JP2019533987A5 JP2019533987A5 (enExample) 2020-10-08
JP7202287B2 true JP7202287B2 (ja) 2023-01-11

Family

ID=61309356

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511562A Active JP7202287B2 (ja) 2016-08-31 2017-08-30 リンパ系疾患の診断及び治療のための組成物及び方法
JP2022206535A Withdrawn JP2023052057A (ja) 2016-08-31 2022-12-23 リンパ系疾患の診断及び治療のための組成物及び方法
JP2024169918A Pending JP2025016454A (ja) 2016-08-31 2024-09-30 リンパ系疾患の診断及び治療のための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022206535A Withdrawn JP2023052057A (ja) 2016-08-31 2022-12-23 リンパ系疾患の診断及び治療のための組成物及び方法
JP2024169918A Pending JP2025016454A (ja) 2016-08-31 2024-09-30 リンパ系疾患の診断及び治療のための組成物及び方法

Country Status (8)

Country Link
US (2) US11401553B2 (enExample)
EP (2) EP4023769A1 (enExample)
JP (3) JP7202287B2 (enExample)
AU (2) AU2017319507B2 (enExample)
CA (1) CA3034786A1 (enExample)
DK (1) DK3506899T3 (enExample)
ES (1) ES2906333T3 (enExample)
WO (1) WO2018045078A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111819A1 (en) * 2018-09-07 2020-03-12 The Children's Hospital Of Philadelphia Compositions and methods for the diagnosis and treatment of lymphatic system disorders
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2023229605A1 (en) * 2022-05-27 2023-11-30 Avalo Therapeutics, Inc. Methods and treatment for complex lymphatic malformations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054280A1 (en) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015095825A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212416D0 (en) 1992-06-11 1992-07-22 Medical Res Council Reversible binding substances
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US9018912B2 (en) 2011-05-17 2015-04-28 Inphi Corporation System and method for managing parallel-connected battery cells
US10835513B2 (en) 2013-06-28 2020-11-17 The Regents Of The University Of California Methods and treatments for the learning and memory deficits associated with Noonan syndrome
JP6429306B2 (ja) * 2014-03-26 2018-11-28 国立大学法人東北大学 Ｃｆｃ症候群モデルマウスの作製とその治療法の確立
WO2018126192A1 (en) 2016-12-30 2018-07-05 Children's Medical Center Corporation Map2k1 (mek1) as a therapeutic target for arteriovenous malformations and associated disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054280A1 (en) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015095825A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Am. J. Respir. Crit. Care Med., 2015, Vol. 191, p. A5454
Am. J. Respir. Crit. Care Med.，2015年，Vol. 191，p. A5454
BioMed research international, 2015, Article ID 870918
BioMed research international，2015年，Article ID 870918
J. Clin. Invest., 2016, Vol. 126, No. 8, pp. 3080-3088
J. Clin. Invest.，2016年，Vol. 126, No. 8，pp. 3080-3088

Also Published As

Publication number Publication date
WO2018045078A3 (en) 2019-04-25
WO2018045078A2 (en) 2018-03-08
EP3506899A2 (en) 2019-07-10
JP2023052057A (ja) 2023-04-11
DK3506899T3 (da) 2022-03-07
EP3506899B1 (en) 2021-12-15
US20200056238A1 (en) 2020-02-20
AU2017319507A1 (en) 2019-03-14
US11401553B2 (en) 2022-08-02
EP4023769A1 (en) 2022-07-06
EP3506899A4 (en) 2020-05-20
ES2906333T3 (es) 2022-04-18
JP2019533987A (ja) 2019-11-28
AU2024201122A1 (en) 2024-03-14
JP2025016454A (ja) 2025-02-04
US20230048706A1 (en) 2023-02-16
AU2017319507B2 (en) 2023-11-23
CA3034786A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
JP2023052057A (ja) リンパ系疾患の診断及び治療のための組成物及び方法
Domigan et al. Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy
WO2010051550A1 (en) Methods of diagnosing and treating fibrosis
JP2025020109A (ja) リンパ系疾患の診断および治療のための組成物および方法
JP2011083279A (ja) 皮膚炎症性疾患の診断方法
Hutter et al. Differential roles of miR‐15a/16‐1 and miR‐497/195 clusters in immune cell development and homeostasis
Hines et al. A sex-specific role of type VII adenylyl cyclase in depression
US20140377379A1 (en) Method for prognosing the age-at-onset of huntington's disease
CN101896815A (zh) 肠疾病中的新的治疗靶标
WO2020143424A1 (zh) 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
HK40079819A (en) Compositions and methods for the diagnosis and treatment of lymphatic system disorders
Talbot et al. Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival
US11499194B2 (en) CXR4 as a susceptibility locus in juvenile idiopathic arthritis (JIA) and methods of use thereof for the treatment and diagnosis of the same
US9820951B2 (en) Pulmonary disease treatment and diagnosis based on Arhgef1
HK40064127A (en) Compositions and methods for the diagnosis and treatment of lymphatic system disorders
WO2007058986A2 (en) Methods for diagnosing and identifying effective therapeutics for major depressive disorder
Schürmann Endogenous opioid peptides in drug addiction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221223

R150 Certificate of patent or registration of utility model

Ref document number: 7202287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250